Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (7256)	4/18/1998 7:48:00 PM
From: Zebra 365	Read Replies (1) \| Respond to of 23519

Regarding the price.... In the US Viagra does carry a retail price less than MUSE, that would seem to give it the edge. However, since Viagra has been approved as an erection "enhancer" (FDA's words, not mine..... fda.gov <<Unlike previously approved treatments for impotence, Viagra does not directly cause penile erections, but affects the response to sexual stimulation.ÿ The drug acts by enhancing the smooth muscle relaxant effects of nitric oxide, a substance that is normally released locally in response to sexual stimulation.>>) and MUSE approved as a treatment for impotence, some pharmacy benefit plans have taken that opportunity to refuse to cover Viagra where they will cover MUSE. I don't have hard data on this, just anecdotal reports. Too soon to tell what will be the policy, but considering the red ink of many insurers, this is not unexpected. But, if this turns out to be the case, then the price to the consumer for a three-month supply of MUSE will often be the same as the price of a single Viagra pill. I agree it is best to see a support level before adding to the portfolio, we should see what the support level is over the next few weeks. When this stock turns up, it will be on solid ground, sales and earnings will drive it this time. Zebra